BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$83.34 USD
-1.32 (-1.56%)
Updated Jul 18, 2024 04:00 PM ET
After-Market: $83.33 -0.01 (-0.01%) 7:18 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Brokerage Reports
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 21 - 40 ( 818 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BMRN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3 Chutes Ladders-VOXZOGO Climbs, ROCTAVIAN Falls as Launch Headwinds Persist
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-The Wedbush Monthly Check-Up: November 2023
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
RD Day: VOXZOGO Drives Growth but ROCTAVIAN Remains a "Show Me" Story
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
1st Patient Dosed with ROCTAVIAN in EU, 1yr Post-Approval; Eyes on YE Execution
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A